Numeric Investors LLC reduced its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 87.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 13,500 shares of the biopharmaceutical company’s stock after selling 90,300 shares during the period. Numeric Investors LLC’s holdings in Emergent Biosolutions were worth $443,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of the stock. Creative Planning raised its stake in Emergent Biosolutions by 146.3% in the third quarter. Creative Planning now owns 10,100 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 6,000 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Emergent Biosolutions by 62.4% in the third quarter. Nisa Investment Advisors LLC now owns 37,200 shares of the biopharmaceutical company’s stock worth $1,173,000 after buying an additional 14,300 shares in the last quarter. Acadian Asset Management LLC raised its stake in Emergent Biosolutions by 1.1% in the third quarter. Acadian Asset Management LLC now owns 1,604,001 shares of the biopharmaceutical company’s stock worth $50,573,000 after buying an additional 16,798 shares in the last quarter. Nationwide Fund Advisors raised its stake in Emergent Biosolutions by 17.4% in the third quarter. Nationwide Fund Advisors now owns 51,243 shares of the biopharmaceutical company’s stock worth $1,616,000 after buying an additional 7,600 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its stake in Emergent Biosolutions by 12.7% in the third quarter. Rice Hall James & Associates LLC now owns 314,645 shares of the biopharmaceutical company’s stock worth $9,921,000 after buying an additional 35,418 shares in the last quarter. 89.61% of the stock is currently owned by institutional investors.
Shares of Emergent Biosolutions Inc (NYSE:EBS) opened at 30.47 on Monday. The firm has a 50-day moving average price of $30.50 and a 200-day moving average price of $29.88. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 26.94 and a beta of 1.02. Emergent Biosolutions Inc has a 52-week low of $24.47 and a 52-week high of $44.38.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, February 23rd. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.26. The firm earned $151.66 million during the quarter, compared to analyst estimates of $120.45 million. Emergent Biosolutions had a return on equity of 10.42% and a net margin of 9.12%. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.77 earnings per share. Analysts predict that Emergent Biosolutions Inc will post $1.52 EPS for the current fiscal year.
Your IP Address:
EBS has been the topic of a number of analyst reports. Chardan Capital set a $47.00 price target on Emergent Biosolutions and gave the company a “buy” rating in a research report on Saturday, December 10th. Cowen and Company reaffirmed a “hold” rating on shares of Emergent Biosolutions in a research report on Monday, January 9th. Finally, Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Wednesday, February 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $39.40.
In related news, EVP Adam Havey sold 8,438 shares of the company’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $29.75, for a total value of $251,030.50. Following the completion of the transaction, the executive vice president now directly owns 41,424 shares in the company, valued at $1,232,364. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Abdun-Nabi sold 28,240 shares of the company’s stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $31.28, for a total value of $883,347.20. Following the completion of the transaction, the insider now owns 172,945 shares of the company’s stock, valued at $5,409,719.60. The disclosure for this sale can be found here. Insiders sold 58,678 shares of company stock valued at $1,793,376 over the last quarter. Insiders own 17.20% of the company’s stock.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/numeric-investors-llc-has-443000-position-in-emergent-biosolutions-inc-ebs/1708823.html
Receive News & Ratings for Emergent Biosolutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.